Incorporated in 1960, Anuh Pharma Ltd is in the business of manufacturing and selling of Bulk drugs and chemicals
The company operates as a low-cost manufacturer of first-generation antibiotics and niche APIs, benefiting from regulatory certifications (USFDA, EDQM, WHO PQ) that act as entry barriers. However, the lack of durable pricing power is evident as margins fluctuate with raw material costs and the company frequently resorts to low-margin trading activities to meet revenue targets.
Capital has been deployed primarily into organic capacity expansion at the Boisar site, increasing capacity from 1,200 MT to 2,400 MT over several years. While the company maintains a debt-free balance sheet and pays consistent dividends, the incremental returns on reinvested capital are dampened by high cash balances and a lack of successful inorganic execution despite years of searching.
Five years out, the investment collapsed as the company's manufacturing core was hollowed out by commoditization, leaving it as little more than a low-margin trading house. The promised capacity expansions at Boisar failed to generate incremental returns as raw material volatility squeezed the narrow margins of first-generation antibiotics. Management's inability to move up the value chain, combined with a persistent refusal to list on the NSE and a lack of transparency regarding related-party transactions, eventually led to a total loss of institutional confidence and a permanent de-rating of the stock.
RichFakir rates Anuh Pharma Ltd's business quality as mediocre — 51/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as narrow.
On our model, Anuh Pharma Ltd is trading about 10% above our estimate of fair value; we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Anuh Pharma Ltd is: Not rated. A mediocre business at an expensive price — it does not make our shortlist right now.
RichFakir's educational estimate of Anuh Pharma Ltd's fair value is about ₹79 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →